Host Cell Protein Clinical Safety Risk Assessment-An Updated Industry Review

Area of Science:

• Biopharmaceutical Manufacturing
• Analytical Chemistry
• Regulatory Science

Background:

• Host cell proteins (HCPs) are process-related impurities co-purifying with therapeutic proteins.
• HCPs can impact patient safety through immunogenicity or toxicity, affecting efficacy and product quality.
• Effective reduction and monitoring of HCPs are crucial for biopharmaceutical development.

Purpose of the Study:

• To develop updated risk assessment frameworks for clinical safety risks of identified HCPs.
• To incorporate regulatory considerations and industry experience into HCP risk management.
• To provide guidance for decision-making in biopharmaceutical development and manufacturing.

Main Methods:

• Review and build upon existing HCP risk assessment frameworks.
• Incorporate industry expert knowledge and regulatory expectations.
• Utilize a real-world case study to illustrate the application of updated frameworks.

Main Results:

• Recommendations for conducting clinical risk assessment alongside product quality risk assessment.
• Emphasis on evaluating biological activity and immunogenicity of concerning HCPs.
• Highlighting the importance of cross-functional communication and collaboration.

Conclusions:

• Comprehensive risk assessment frameworks are essential for managing HCPs in biopharmaceuticals.
• Proactive identification and assessment of HCPs mitigate risks to patient safety.
• Updated frameworks support regulatory compliance and continuous process improvement.